Free accessResearch articleFirst published online 2000-12
Cardioprotection Induced by AT1R Blockade After Reperfused Myocardial Infarction: Association With Regional Increase in AT2R,IP3R and PKCε Proteins and cGMP
Background: We hypothesized that the cardioprotective effect of angiotensin II (AngII) type 1 receptor (AT,R) blockade during in vivo ischemia-reperfusion (IR) might be associated with an increase in AngII type 2 receptor (AT2R) protein, as well as 1,4,5-inositol trisphosphate type 2 receptor (IP3R) and protein kinase Cε, (PKCε) proteins and cyclic guanosine 3',5' monophosphate (cGMP).
Methods and Results: We studied the effects of the AT1R blocker, candesartan, on in vivo left ventricular (LV) systolic and diastolic function and remodeling (echocardiogram/Doppler) and hemodynamics during canine reperfused anterior infarction (90-minute ischemia, 120-minute reperfusion), and ex vivo infarct size and AT1R/AT2R, IP3R, and PKCε proteins (immunoblots), and cGMP (enzyme immunoassay). Compared with controls, candesartan (1 mg/kg intravenously over 30-minute preischemia) inhibited the AngII pressor response, decreased preload and afterload, improved LV systolic and diastolic function, limited LV remodeling, decreased infarct size (55% vs 27% risk; P < .000003), markedly increased AT2R, IP3R, and PKCε proteins in the infarct zone, but not the AT,R protein, and increased infarct more than noninfarct cGMP.
Conclusions: The overall results suggest that cardioprotective effects of AT1R blockade on acute IR injury might involve AT2R activation and downstream signaling via IP3R, PKCε, and cGMP.
Jugdutt BIAngiotensin II receptor blockers. In Crawford MH (ed): 1998 Cardiology Clinics Annual of Drug Therapy (vol 2). Saunders, Philadelphia, PA, pp. 1-17, 1998
2.
Pitt B., Segal R., Martinez FA,et al, on behalf of the ELITE Study Investigators.Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in Elderly Study, ELITE). Lancet349:747, 1997
3.
Ford WR, Khan MI, Jugdutt BIEffect of the novel angiotensin II type 1 receptor antagonist L-158,809 on acute infarct expansion and acute anterior myocardial infarction in the dog . Can J Cardiol14:73, 1998
4.
Jalowy A., Schulz R., Dörge H., et al. Infarct size reduction by AT,-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol32:1787, 1998
5.
Pitt B., Poole-Wilson PA, Segal R., et al. Losartan Heart Failure Survival Study - Elite II. Circulation100:I-782, 1999 (abstr)
6.
McKelvie RS, Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation100:1056, 1999
7.
Kitakaze M., Minamino T., Node K., et al. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation92:950, 1995
8.
Dörge H., Behrends M., Schulz R., et al. Attenuation of myocardial stunning by the AT1 receptor antagonist candesartan. Basic Res Cardiol94:208, 1999
9.
Werrmann JG, Cohen SMComparison of the effects of angiotensin converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in the post-ischemic working rat heart as studied by 31Pnuclear magnetic resonance . J Cardiovasc Pharmacol24:573, 1994
10.
Yoshiyama M. , Kim S., Yamagishi H., et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J128:1, 1994
11.
Yang BC, Phillips MI, Ambeuhl Pej, et al. Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation96:922, 1997
12.
Yang BC, Phillips MI, Zhang YC, et al. Critical role of AT1 receptor expression after ischemia/reperfusion in isolated rat hearts: Beneficial effect of antisense ligodeoxynucleotides directed at AT1 receptor mRNA. Circ Res83:552, 1998
13.
Ford WR, Clanachan AS, Jugdutt BIOpposite effects of angiotensin receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts . Circulation94:3087, 1996
14.
Ford WR, Clanachan AS, Lopaschuk GD, et al. Intrinsic AngII type 1 receptor stimulation contributes to recovery of postischemic mechanical function. Am J Physiol274:H1524, 1998
15.
Kohya T., Yokoshiki H., Tohse N., et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias: Beneficial effect of angiotensin II blockade. Circ Res76:892, 1995
16.
Wiemer G., Schölkens BA, Wagner A., Heitsch H., Linz W.The possible role of angiotensin II subtype AT2 receptors in endothelial cells and isolated ischemic rat hearts. J Hypertens11:S234, 1993
17.
Thomas GP, Ferrier GR, Howlett SELosartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharmacol Exp Ther278:1090, 1996
18.
Schwarz ER, Montino H., Fleischhauer J., et al. Angiotensin II receptor antagonist EXP3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart . Cardiovasc Drugs Ther11:687, 1997
19.
Liu Y-H., Yang X-P., Sharov VG, et al. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension27:7, 1996
20.
Sladek T., Sladkova J., Kolar F., et al. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res31:568, 1996
21.
Stauss HM, Zhu Y-C., Redlich T., et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: Bradykinin versus angiotensin II. J Cardiovasc Risk1:255, 1994
22.
Liu Y., Tsuchida A., Cohen MV, et al. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol27:883, 1995
23.
Diaz RJ, Wilson GJSelective blockade of AT, angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Moll Cell Cardiol29:129, 1997
24.
Richard V., Ghaleh B., Berdeaux A., et al. Comparison of the effects of EXP3174, an angiotensin II antagonist, and enalaprilat on myocardial infarct size in anesthetized dogs. Br J Pharmacol110:969, 1993
25.
McDonald KM , Garr M., Carlyle PF, et al. Relative effects of α 1-adrenoreceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation90:3034, 1994
26.
Hartman JC, Hullinger TG, Wall TM, et al. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol234:229, 1993
27.
Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists in rats with heart failure: Role of kinins and angiotensin type 2 receptors. J Clin Invest99:1926, 1997
28.
Milavetz JJ , Raya TE, Johnson CS, et al. Survival after myocardial infarction in rats: Captopril versus losartan. J Am Coll Cardiol27:714, 1996
29.
Richer C., Fornes P., Cazaubon C., et al. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc Res41:100, 1999
30.
Bastien NR, Juneau A-V.,Ouellette J., et al. Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: Effects on cardiac hypertrophy and survival. Cardiovasc Res43:77, 1999
31.
Yusuf S., Maggioni AP, Rouleau JLEffects of candesartan, enalapril or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD). Circulation96:1-452, 1997 (suppl) (abstr)
32.
Bartunek J. , Weinberg EO, Tajima M., et al. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation99:22, 1999
33.
Tasker PN, Michelangeli F., Nixon GFExpression and distribution of the type 1 and type 3 inositol 1,4,5-trisphosphate receptor in developing vascular smooth muscle. Circ Res84:536, 1999
34.
Perez PJ, Ramos-Franco J., Fill M., et al. Identification and functional reconstitution of the type 2 inositol 1,4,5-trisphosphate receptor from ventricular cardiac myocytes. J Biol Chem272:23961, 1997
35.
Vanderheyden Pml, Fierens Flp, De Backer JP, et al. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT 1 receptors. Br J Pharmacol126:1057, 1999
36.
Jugdutt BI, Khan MI, Jugdutt SJ, et al. Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation92:926, 1995
37.
Jugdutt BIEffect of reperfusion on ventricular mass, topography and function during healing of anterior infarction. Am J Physiol272:H1205, 1997
38.
Douglas PS, Tallant B.Hypertrophy, fibrosis and diastolic dysfunction in early canine experimental hypertension. J Am Coll Cardiol17:530, 1991
39.
Klein HH, Puschmann S., Schaper J., et al. The mechanism of the tetrazolium reaction in identifying experimental myocardial infarction. Virchows Arch393:287, 1981
40.
Gregg DE, Patterson REFunctional importance of the coronary collaterals. N Engl J Med303:1404, 1981
41.
Jugdutt BI, Becker LC, Hutchins GMEarly changes in collateral blood flow during myocardial infarction in conscious dogs. Am J Physiol237:H371, 1979
42.
Becker LC, Jeremy RW, Schaper J., et al. Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog. Am J Physiol277:H243, 1999
43.
Seyedi N., Xu XB, Nasjletti A., Hintze THCoronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension26:164, 1995
44.
Gohlke P., Pees C., Unger T.AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension31:349, 1998
45.
Christen Y. , Waeber B., Nussberger J., et al. Oral administration of DuP753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation83:1333, 1991
46.
Hübner R., Högemann AM, Sunzel M., et al. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly human volunteers. J Hum Hypertens11:S19, 1997 (suppl)
47.
Stoll M., Steckelings UM, Paul M., et al. The angiotensin AT2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest95:651, 1995
48.
Yamada T., Horiuchi M., Dzau VJAngiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A93:156, 1996
49.
Tanaka M., Tsuchida S., Imai T., et al. Vascular response to angiotensin II is exaggerated through an upregulation of AT1 Receptor in AT2 knockout mice. Biochem Biophys Res Commun258:194, 1999
50.
Siragy HM, Inagami T., Ichiki T., et al. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A96:6506, 1999
51.
Masaki H., Kurihara T., Yamaki A., et al. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest101:527, 1998
52.
Ichiki T., Usui M., Kato M., et al. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension31:342, 1998
53.
Laursen JB, Rajagopalan S., Galis Z., et al Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation95:588, 1997
54.
Yasmin W., Strynadka KD, Schulz R.Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res33:422, 1997
55.
Horiuchi M. , Akishita M., Dzau VJRecent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension33:613, 1999
56.
Ping P., Takano H., Zhang J., et al. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits. A signaling mechanism for both nitric-oxide-induced and ischemia-induced preconditioning. Circ Res84:587, 1999
57.
Rabkin SWCardiac angiotensin II subtype 2 receptor signal transduction pathways: Embryonic cardiomyocytes and human heart, in Dhalla NS, Zahradka P, Dixon I, Beamish R (eds): Angiotensin II Receptor Blockade: Physiological and Clinical Implications . Kluwer Academic, Boston, pp. 367-384, 1998
58.
Nio Y., Matsubara H., Murasawa S., et al. Regulation and gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest95:46, 1995
59.
Lopez JJ, Lorell BH, Ingelfinger JR, et al. Distribution and function of cardiac angiotensin AT1-and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol267:H844, 1994
60.
Kijima K., Matsubara H., Murasawa S., et al. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res79:887, 1996
61.
Haywood GA, Gullestad L., Katsuya T., et al. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation95:1201, 1997
62.
Wharton J., Morgan K., Rutherford Rad, et al. Differential distribution of angiotensin AT2-receptors in the normal and failing human heart. J Pharmacol Exp Ther284:323, 1998
